情报研究

基于指数随机图模型的专利引用关系形成机制研究——以奈拉滨药物为例

  • 杨冠灿 ,
  • 刘占麟 ,
  • 李纲
展开
  • 1. 中国人民大学信息资源管理学院 北京 100872;
    2. 华盛顿大学工业工程系 西雅图 98105;
    3. 武汉大学信息管理学院 武汉 430072
杨冠灿(ORCID:0000-0002-1706-1884),讲师,博士,E-mail:yanggc@ruc.edu.cn;刘占麟,博士研究生;李纲(ORCID:0000-0001-5573-6400),教授,博士,博士生导师。

收稿日期: 2018-08-05

  修回日期: 2018-11-27

  网络出版日期: 2019-05-20

基金资助

本文系国家自然科学基金项目"基于指数随机图模型的专利引用关系形成影响因素及机理研究"(项目编号:71403256)、国家自然科学基金项目"面向专利文本中实体关系抽取的远程监督方法研究"(项目编号:71704169)和国家自然科学基金重大项目"国家安全大数据综合信息集成与分析方法"(项目编号:71790612)研究成果之一。

Understanding Mechanisms of Patent Citation Formation Based on ERGM: A Case Study of the Nelarabine Drug

  • Yang Guancan ,
  • Liu Zhanlin ,
  • Li Gang
Expand
  • 1. School of Information Resource Management of Renmin University of China, Beijing 1000872;
    2. Department of Industrial and Systems Engineering, University of Washington, Seattle 98105;
    3. School of Information Management of Wuhan University, Wuhan 430072

Received date: 2018-08-05

  Revised date: 2018-11-27

  Online published: 2019-05-20

摘要

[目的/意义] 专利引用关系形成问题是理解创新网络的一个重要问题。传统的回归模型对观察对象设定的独立性假设,无法将网络的结构效应因素整合到模型中来提供综合性的统计推断。指数随机图模型(ERGM,Exponential Random Graph Model)是一种创新性的统计推断方法,它能够将属性特征、自组织特征以及网络协同特征三种特征综合起来观察。[方法/过程] 以奈拉滨药物的专利引文网络作为研究对象,利用ERGM系统检验了影响专利引用关系的五种机制:专利属性的主效应;专利引用时间的差值效应;专利引用关系的聚敛效应;专利引用关系的传递效应;专利引用关系的网络协同效应。[结果/结论] 五种机制都在奈拉滨药物的专利引用关系的形成过程发挥了作用。但三种效应对于奈拉滨药物的专利引用关系的形成作用最为显著:共享发明人关系协同效应、共享家族关系协同效应、传递效应。一些辅助机制也会对专利引文关系形成产生影响,如引文时滞、权利要求数量和参考文献数量。

本文引用格式

杨冠灿 , 刘占麟 , 李纲 . 基于指数随机图模型的专利引用关系形成机制研究——以奈拉滨药物为例[J]. 图书情报工作, 2019 , 63(10) : 75 -86 . DOI: 10.13266/j.issn.0252-3116.2019.10.009

Abstract

[Purpose/significance] The Formation of patent citation is necessary to understand innovation networks. The independence assumption set by the Conventional regression model for observed objects cannot integrate the structural effect factors of the network into the model to provide comprehensive statistical inference. ERGMs (exponential random graph model) represent a methodological innovation of statistical inference for networks given their ability to model actor attributes along with endogenous self-organizational processes and exogenous network covariates.[Method/process] In this paper, ERGMs are applied to systematic inspect the five mechanisms affecting patent citation formation in a sample of Nelarabine drug. The five mechanisms contain main effect, difference effect of citation lag, and activity effect, transitivity effect and network covariates.[Result/conclusion] We find that five different types of mechanisms play diverse roles in patent citation formation. And three of effects among these mechanisms have significant impacts on citation formation of nelarabine drug:network covariates based on shared inventors and shared patent family membership, and transitivity effect. In addition, some aided mechanism play a supporting role on patent citation formation, such as difference of time lag, main effects of number of claims and reference.

参考文献

[1] OECD. OECD patent statistics manual[M]. Paris:OECD Publishing, 2009.
[2] JAFFE A B, DE RASSENFOSSE G. Patent citation data in social science research:overview and best practices[J]. Journal of the Association for Information Science and Technology, 2017, 68(6):1360-1374.
[3] YANG G C, LI G, LI C Y, Using the comprehensive patent citation network (CPC) to evaluate patent value[J]. Scientometrics, 2015, 105(3):1319-1346.
[4] VAN RAAN A F J. Patent citations analysis and its value in research evaluation:a review and a new approach to map technology-relevant research[J]. Journal of data and information science, 2017, 2(1):545-538.
[5] MORRIS S A, VAN DER VEER MARTENS B. Mapping research specialties[J]. Annual review of information science and technology, 2008, 42(1):213-295.
[6] ARRIETA PAREDES M P, CRONIN B. Exponential random graph models for management research:a case study of executive recruitment[J]. European management journal, 2017, 35(3):373-382.
[7] ROSE KIM J Y, HOWARD M, COX PAHNKE E. Understanding network formation in strategy research:exponential random graph models[J]. Strategic management journal, 2016, 37(1):22-44.
[8] GOODREAU S M, HANDCOCK M S, BUTTS C T. Statnet:software tools for the representation, visualization, analysis and simulation of network data[J]. Journal of statistical software, 2008, 24(1):1-11.
[9] ROBINS G, PATTISON P, KALISH Y. An introduction to exponential random graph (p*) models for social networks[J]. Social networks, 2007, 29(2):173-191.
[10] JAFFE A B, TRAJTENBERG M. Patents, citations, and innovations[M]. New York:MIT Press, 2002.
[11] ALCÁCER J, GITTELMAN M. Patent citations as a measure of knowledge flows:the influence of examiner citations[J]. Review of economics and statistics, 2006, 88(4):774-779.
[12] ROBINS G. Doing social network research[M]. London:SAGE, 2015.
[13] FISCHER T, LEIDINGER J. Testing patent value indicators on directly observed patent value-an empirical analysis of Ocean Tomo patent auctions[J]. Research policy, 2014, 43(3):519-529.
[14] ALCÁCER J, GITTELMAN M, SAMPAT B. Applicant and examiner citations in U.S. patents:an overview and analysis[J]. Research policy, 2009, 38(2):415-427.
[15] HALL B H, JAFFE A B, TRAJTENBERG M. The NBER patent citation data file:lessons, insights and methodological tools[R].Cambridge:National Bureau of Economic Research, 2001.
[16] BENSON C L, MAGEE C L. Quantitative determination of technological improvement from patent data[J]. Public library of science, 2015, 10(4):e0121635.
[17] CZARNITZKI D, HUSSINGER K, SCHNEIDER C. "Wacky" patents meet economic indicators[J]. Economics letters, 2011, 113(2):131-134.
[18] SMILKOV D, KOCAREV L. Rich-club and page-club coefficients for directed graphs[J]. Physica a:statistical mechanics and its applications, 2010, 389(11):2290-2299.
[19] BRANTLE T F, FALLAH M H. Complex innovation networks, patent citations and power laws[C]//PICMET'07-2007 Portland international conference on management of engineering & technology. Portland:IEEE,2007:540-549.
[20] WANG J C, CHIANG C H, LIN S W. Network structure of innovation:can brokerage or closure predict patent quality?[J]. Scientometrics, springer netherlands, 2010, 84(3):735-748.
[21] BATAGELJ V. Efficient algorithms for citation network analysis[EB/OL].[2017-12-31]. https://arxiv.org/abs/cs/0309023.pdf.
[22] HUNG S W, WANG A P. Examining the small world phenomenon in the patent citation network:a case study of the radio frequency identification (RFID) network[J]. Scientometrics, 2009, 82(1):121-134.
[23] ALMEIDA P, KOGUT B. The exploration of technological diversity and geographic localization in innovation:start-up firms in the semiconductor industry[J]. Small business economics, 1997, 9(1):21-31.
[24] WHITE H D, WELLMAN B, NAZER N. Does citation reflect social structure?:Longitudinal evidence from the "Globenet" interdisciplinary research group[J]. Journal of the Association for Information Science and Technology, 2004, 55(2):111-126.
[25] YAN E, DING Y. Scholarly network similarities:how bibliographic coupling networks, citation networks, cocitation networks, topical networks, coauthorship networks, and coword networks relate to each other[J]. Journal of the Association for Information Science and Technology, 2012, 63(7):1313-1326.
[26] SNIJDERS T A B, PATTISON P E, ROBINS G L. New specifications for exponential random graph models[J]. Sociological methodology, 2006, 36(1):99-153.
[27] ROBINS G, SNIJDERS T, WANG P. Recent developments in exponential random graph (p*) models for social networks[J]. Social networks, 2007, 29(2):192-215.
[28] THORNE N, AULD D S, INGLESE J. Apparent activity in high-throughput screening:origins of compound-dependent assay interference[J]. Current opinion in chemical biology, 2010, 14(3):315-324.
[29] LIM S Y, SUH M. Intellectual property business models using patent acquisition:a case study of royalty pharma inc[J]. Journal of commercial biotechnology, 2016, 22(2):6-18.
[30] WAGNER S, WAKEMAN S. What do patent-based measures tell us about product commercialization? evidence from the pharmaceutical industry[J]. Research policy, 2016, 45(5):1091-1102.
[31] KISOR D F. Collaboration to meet a therapeutic need:the development of nelarabine[J/OL]. Clinical nedicine. 2009, 1:1317-1320.[2018-12-06]. https://dio.org/10.4137/CMT.s2909.
[32] FDA approval for nelarabine[EB/OL].[2017-12-06]. https://www.cancer.gov/about-cancer/treatment/drugs/fda-nelarabine.
[33] COHEN M H, JOHNSON J R, JUSTICE R. FDA drug approval summary:nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma[J]. The oncologist, 2008, 13(6):709-714.
[34] KADIA T M, GANDHI V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma[J]. Expert review of hematology, 2016, 10(1):1-8.
[35] PAPADATOS G, DAVIES M, DEDMAN N. SureChEMBL:a large-scale, chemically annotated patent document database[J]. Nucleic acids research, 2016, 44(D1):D1220-D1228.
[36] MARRA M, EMROUZNEJAD A, HO W. The value of indirect ties in citation networks:SNA analysis with OWA operator weights[J]. Information sciences, 2015, 314:135-151.
[37] LUKE D. A user's guide to network analysis in R[M]. Cham:Springer International Publishing, 2015.
[38] DUBNJAKOVIC A. An evaluation of exponential random graph modeling and its use in library and information science studies[J]. Library & information science research, 2016, 38(3):259-264.
[39] ROBINS G, PATTISON P, WANG P. Closure, connectivity and degree distributions:exponential random graph (p*) models for directed social networks[J]. Social networks, 2009, 31(2):105-117.
文章导航

/

〈 〉